Debt-to-EBITDA measures a company's ability to pay off its debt.
Illumina's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2022 was $571 Mil. Illumina's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2022 was $2,044 Mil. Illumina's annualized EBITDA for the quarter that ended in Mar. 2022 was $948 Mil.
Illumina's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2022 was 2.76.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Illumina's Debt-to-EBITDA or its related term are showing as below:
ILMN'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.08 Med: 1.76 Max: 2.93
Current: 2.19
During the past 13 years, the highest Debt-to-EBITDA Ratio of Illumina was 2.93. The lowest was 1.08. And the median was 1.76.
Illumina Debt-to-EBITDA Historical Data
The historical data trend for Illumina's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
|
Illumina Annual Data
|
|
Trend |
Dec12 |
Dec13 |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
| Debt-to-EBITDA |
|
|
|
|
|
|
1.08 |
1.77 |
1.39 |
1.75 |
2.12 |
|
Illumina Quarterly Data
|
|
Jun17 |
Sep17 |
Dec17 |
Mar18 |
Jun18 |
Sep18 |
Dec18 |
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
| Debt-to-EBITDA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.05 |
2.24 |
1.27 |
3.38 |
2.76 |
Competitive Comparison
For the Diagnostics & Research subindustry, Illumina's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Illumina Debt-to-EBITDA Distribution
For the Medical Diagnostics & Research industry and Healthcare sector, Illumina's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Illumina's Debt-to-EBITDA falls into.
Illumina Debt-to-EBITDA Calculation
Debt-to-EBITDA measures a company's ability to pay off its debt.
Illumina's Debt-to-EBITDA for the fiscal year that ended in Dec. 2021 is calculated as
Illumina's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2022) EBITDA data.
Illumina Business Description
Traded in Other Exchanges
Address
5200 Illumina Way, San Diego, CA, USA, 92122
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates revenue from sequencing tools and dedicated consumables (76% of 2020 sales). Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications. Services account for 16% of sales and include basic maintenance services, clinical lab applications (such as noninvasive prenatal, oncology, and rare-disease screening), and whole genome sequencing.
Executives
| Flatley Jay T |
director |
9885 TOWNE CENTRE DR SAN DIEGO CA 92121 |
| Tousi Susan H |
officer: SVP Product Development |
5200 ILLUMINA WAY SAN DIEGO CA 92122 |
| Reeves Kathryne Gambrell |
officer: SVP, Chief Marketing Officer |
5200 ILLUMINA WAY SAN DIEGO CA 92122 |
| Goswami Joydeep |
officer: SVP Corp Business Development |
SUMITOMO FUDOSAN MITA TWIN BLDG EAST WING 4-2-8 SHIBAURA MINATO-KU TOKYO M0 1080023 |
| Dadswell Charles |
officer: SVP & General Counsel |
5200 ILLUMINA WAY SAN DIEGO CA 92122 |
| Desouza Francis A |
director, officer: President and CEO |
350 ELLIS STREET MOUNTAIN VIEW CA 94043 |
| Van Oene Mark |
officer: SVP Chief Commercial Officer |
5200 ILLUMINA WAY SAN DIEGO CA 92122 |
| Ragusa Robert P |
officer: SVP, Global Quality & Ops |
PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: RAGUSA ROBERT P a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;} |
| Mcginnis Karen K |
officer: VP, Chief Accounting Officer |
INSIGHT ENTERPRISES INC 1305 WEST AUTO DRIVE TEMPE AZ 85284 |
| Hoyt Aimee L |
officer: SVP, Chief People Officer |
5200 ILLUMINA WAY SAN DIEGO CA 92122 |
| Ronaghi Mostafa |
officer: SVP, Entrepreneurial Devlopmt |
9885 TOWNE CENTRE DRIVE SAN DIEGO CA 92121 |
| Aravanis Alexander |
officer: SVP, Chief Technology Officer |
5200 ILLUMINA WAY SAN DIEGO CA 92122 |
| Siegel Susan E |
director |
3000 SAND HILL ROAD BLDG 3 STE 290 MENLO PARK CA 94025 |
| Thompson John Wendell |
director |
C/O MICROSOFT CORPORATION ONE MICROSOFT WAY REDMOND WA 98053 |
| Epstein Robert S |
director |
PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: EPSTEIN ROBERT S a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;} |
Illumina Headlines
By Seekingalpha 2022-02-10
By tipranks.com 2022-03-30
By tipranks.com 2022-03-02
By Seekingalpha 2022-01-10
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
9.48(0%) Volume: 1,224,710 10:08PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:ILMN has been successfully added to your 